Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Determining the Safety of CAR T-Cell Therapy for Lymphoma

13. November 2026 aktualisiert von: University of Chicago

Phase I Dose-Escalation/Expansion Study of Anti-CD19/CD22 CAR T-Cell Therapy for Relapsed/Refractory Mature B-cell Lymphoma After Prior CD19 CAR T-Cell Failure

This study seeks to determine the safety of CAR T-cell therapy in participants with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).

Studienübersicht

Detaillierte Beschreibung

This study seeks to determine the safety of CAR T-cell therapy in participants with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).

When non-Hodgkin lymphoma returns (relapses) or stops responding to treatment (refractory), standard options like chemotherapy or common targeted drugs can become ineffective. This study evaluates a treatment approach called CAR T-cell therapy. CAR T-cell therapy uses a participant's own immune cells (T cells) to hunt down and fight cancer.

Participants in this study will first have their T cells collected through a process called leukapheresis, where blood is drawn, spun through a machine to filter out T cells, and the remaining blood is returned to the body. In the laboratory, these T cells are modified with a Chimeric Antigen Receptor (CAR) protein, which acts like a targeting system to help the T cells recognize two specific markers on lymphoma cells: Cluster of Differentiation 19 (CD19) and Cluster of Differentiation 22 (CD22). The modified CAR T-cells are then given back to the participant through an intravenous (IV) infusion.

The main goal of this study is to find the safest and most effective dose of anti-CD19/CD22 CAR T-cells without causing unexpected or severe side effects. The study also evaluates how the body reacts to the treatment and measures how well the therapy works at shrinking or eliminating the cancer.

Studientyp

Interventionell

Einschreibung (Geschätzt)

36

Phase

  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • Illinois
      • Chicago, Illinois, Vereinigte Staaten, 60637
        • The University of Chicago Medicine Comprehensive Cancer Center
        • Kontakt:
        • Hauptermittler:
          • Alexandra E. Rojek, MD

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) Performance status ≤ 2
  • At least 1 measurable lesion according to the Lugano Response Criteria for Malignant Lymphoma70
  • Measurable disease defined as ≥ 1 measurable nodal lesion (long axis > 1.5 cm and short axis > 1.0 cm) or ≥ 1 measurable extranodal lesion (long axis > 1.0 cm) on computed tomography (CT) or magnetic resonance imaging (MRI)
  • Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy
  • Total bilirubin ≤ 2.0 mg/dL (or < 3.0 mg/dL for subjects with Gilbert's syndrome or lymphomatous infiltration of the liver)
  • Alanine aminotransferase (AST) and aspartate aminotransferase (AST) ≤ 3 x upper limit of normal (ULN); or ≤ 5 x ULN if known lymphomatous infiltration of the liver
  • Creatinine clearance (as estimated by Cockcroft Gault) ≥ 30 mL/min
  • Adequate cardiac function as defined by left ventricular ejection fraction (LVEF) ≥ 40% as assessed by echocardiography, multigated acquisition scan (MUGA), or cardiac MRI
  • Baseline oxygen saturation ≥ 92% on room air
  • Adequate bone marrow function without growth factor support with short-acting G-CSF within the previous 7 days or long-acting G-CSF within the previous 14 days, and without transfusion support within 7 days prior to apheresis:
  • Absolute neutrophil count (ANC) ≥ 1,000/microliter (µL)
  • Absolute lymphocyte count (ALC) ≥ 100/microliter (µL)
  • Platelets ≥ 50,000/microliter (µL)
  • Hemoglobin ≥ 7g/dL
  • Subjects must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • The presence of any of the following will exclude a subject from study enrollment:
  • Presence of acute or extensive chronic graft versus host disease (GVHD).
  • Active central nervous system or meningeal involvement by lymphoma. Subjects with untreated brain metastases/central nervous system (CNS) disease will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Patients with a history of CNS or meningeal involvement must be in a documented remission by cerebrospinal fluid (CSF) evaluation and contrast-enhanced MRI imaging for at least 90 days prior to registration.
  • History of another primary malignancy that has not been in remission for at least 2 years. The following are examples of exemptions from the 2-year limit: nonmelanoma skin cancer, definitively treated stage 1 solid tumor with low risk for recurrence, curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on papanicolaou (PAP) smear, and in situ breast cancer that has been completely resected.
  • HIV seropositivity.
  • Subjects with uncontrolled intercurrent illness.
  • Pregnant or breastfeeding women are excluded from this study because CAR T-cell therapy may be associated with the potential for teratogenic or abortifacient effects. Women of childbearing potential must have a negative serum pregnancy test. Subjects of either sex who are not willing to practice birth control from the time of consent and at least 6 months after protocol-directed CAR T-cell infusion are excluded (see Section 9.6 for contraception method). Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with CAR T-cells, breastfeeding should be discontinued. These potential risks may also apply to other agents used in this study.
  • Serologic status reflecting active hepatitis B or C infection. Patients that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. (PCR positive patients will be excluded.)
  • Presence of an active and clinically relevant CNS disorder such as epilepsy, generalized seizure disorders, paresis, aphasia, stroke, uncontrolled cerebrovascular disease, cerebellar disease, severe brain injuries, dementia and Parkinson's disease
  • History of autoimmune disease (i.e. rheumatoid arthritis, systemic lupus erythematosus) with requirement of immunosuppressive medication within 6 months.
  • Patients who have received >1 prior CAR T-cell infusion. Patients treated with multiple CAR T-cell infusions in the context of a prior prospective therapeutic clinical trial will be permitted.
  • Any medical condition likely to interfere with assessment of safety or efficacy of study treatment
  • History of severe immediate hypersensitivity reaction to tocilizumab, anakinra or any of the agents used in this study
  • Major surgery within 28 days prior to start of lymphodepleting chemotherapy or any planned medical/surgical treatment that might interfere with the ability to comply with the study requirements.
  • Patients must have a washout period of at least 2 weeks or 5 half-lives, whichever is shorter, since any prior cancer therapy, at the time the patient undergoes apheresis, except as follows:
  • Treatment with alemtuzumab or bendamustine within 6 months of apheresis, or treatment with fludarabine, melphalan, or cladribine within 3 months of apheresis
  • Allogeneic hematopoietic stem cell transplant within 12 weeks prior to apheresis
  • Therapeutic doses of corticosteroids (defined as > 20 mg/day prednisone or equivalent) within 5 days prior to apheresis. Physiologic replacement, topical, and inhaled steroids are permitted.
  • Oral targeted agents, including lenalidomide and ibrutinib, are allowed if at least 3 half-lives have elapsed prior to apheresis.
  • Experimental agents within 4 weeks of apheresis unless no response or disease progression is documented on the experimental therapy and at least 3 half-lives have elapsed prior to apheresis
  • Radiation within 6 weeks of apheresis. Subjects must have progressive disease in irradiated lesions or have additional non-irradiated, PET-positive lesions to be eligible. Radiation to a single lesion or lesions, if additional non-irradiated PET-positive lesions are present, is allowed up to 2 weeks prior to apheresis.
  • Prior cell, gene, or antibody-based therapy (approved or investigational) targeting both cluster of differentiation 19 (CD19) and cluster of differentiation 22 (CD22).
  • Prior bispecific T-cell engaging antibody therapy targeting cluster of differentiation 20 (CD20), cluster of differentiation 19 (CD19), or cluster of differentiation 22 (CD22) on B-cells: a minimum of 30 days must have elapsed between the last dose of bispecific T-cell engaging antibody therapy and apheresis.
  • CD19-directed CAR T-cell infusion within 12 weeks of planned apheresis.
  • Prior cell, gene, or antibody-based therapy (approved or investigational) targeting both CD19 and CD22.
  • Prior bispecific T-cell engaging antibody therapy targeting CD20, CD19, or CD22 on B-cells: a minimum of 30 days must have elapsed between the last dose of bispecific T-cell engaging antibody therapy and apheresis.
  • CNS prophylaxis (e.g., intrathecal methotrexate): must be stopped at least 1 week prior to apheresis
  • Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin-2 [IL-2]) within 6 weeks or 5 half-lives of the drug, whichever is shorter, prior to apheresis.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Nicht randomisiert
  • Interventionsmodell: Sequenzielle Zuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Dose-Finding (Dose Escalation) Group

This group is part of the dose-finding phase of the study. The goal of this phase is to find the safest and most effective dose of CAR T-cell therapy with the fewest side effects.

Participants in this group will first receive lymphodepleting chemotherapy with fludarabine (30 mg/day) and cyclophosphamide (300 mg/day) daily for 3 days (given 5 to 3 days before the T-cell infusion).

After completing chemotherapy, participants will receive a single infusion of CAR-positive T-cells. They will receive 1 of 4 dose levels of CAR T-Cells based on when they join the study and side effects to each dose level. Up to 18 participants will be in this group.

  • Dose Level -1 (Lowered Dose): 5 x 10^5 cells/kg (500,000 cells/kg) given as a single intravenous (IV) infusion. Dose level -1 is a lowered dose that will be given if participants have serious side effects to the starting dose (dose level 1).
  • Dose Level 1 (Starting Dose): 1 x 10^6 cells/kg (1,000,000 cells/kg) given as a single intravenous (IV) infusion
  • Dose Level 2: 2 x 10^6 cells/kg (2,000,000 cells/kg) given as a single intravenous (IV) infusion
  • Dose Level 3: 3 x 10^6 cells/kg (3,000,000 cells/kg) given as a single intravenous (IV) infusion
Andere Namen:
  • CAR T-Cell Therapy, T-Cell Therapy

Fludarabine: 30 mg will be given by intravenous (IV) infusion daily for 3 days (given 5 to 3 days before T-cell infusion). Note: The fludarabine dose remains the same (30 mg) across all dose levels (Level -1 through Level 3).

Andere Namen:
  • Fludara
  • Fludarabinphosphat

Cyclophosphamide: 300 mg given by intravenous (IV) infusion daily for 3 days (given 5 to 3 days before T-cell infusion). Note: The cyclophosphamide dose remains the same (300 mg) across all dose levels (Level -1 through Level 3).

Andere Namen:
  • Cytoxan
  • Neosar
Experimental: Dose Expansion Group

This group is part of the dose expansion phase of the study. The goal of this phase is to further test the dose of CAR T-cell therapy that was selected during the dose-finding phase.

Participants in this group will first receive chemotherapy with fludarabine (30 mg/day) and cyclophosphamide (300 mg/day) daily for 3 days (given 5 to 3 days before the T-cell infusion).

After completing chemotherapy, participants will receive a single infusion of CAR-positive T-cells at the selected dose. Up to 36 participants will be in this group.

  • Dose Level -1 (Lowered Dose): 5 x 10^5 cells/kg (500,000 cells/kg) given as a single intravenous (IV) infusion. Dose level -1 is a lowered dose that will be given if participants have serious side effects to the starting dose (dose level 1).
  • Dose Level 1 (Starting Dose): 1 x 10^6 cells/kg (1,000,000 cells/kg) given as a single intravenous (IV) infusion
  • Dose Level 2: 2 x 10^6 cells/kg (2,000,000 cells/kg) given as a single intravenous (IV) infusion
  • Dose Level 3: 3 x 10^6 cells/kg (3,000,000 cells/kg) given as a single intravenous (IV) infusion
Andere Namen:
  • CAR T-Cell Therapy, T-Cell Therapy

Fludarabine: 30 mg will be given by intravenous (IV) infusion daily for 3 days (given 5 to 3 days before T-cell infusion). Note: The fludarabine dose remains the same (30 mg) across all dose levels (Level -1 through Level 3).

Andere Namen:
  • Fludara
  • Fludarabinphosphat

Cyclophosphamide: 300 mg given by intravenous (IV) infusion daily for 3 days (given 5 to 3 days before T-cell infusion). Note: The cyclophosphamide dose remains the same (300 mg) across all dose levels (Level -1 through Level 3).

Andere Namen:
  • Cytoxan
  • Neosar

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Safe Dose Level (Recommended Phase 2 Dose)
Zeitfenster: Day 30 after CAR T-cell infusion

To find the safest dose of anti-CD19/22 CAR T-cells as assessed by tracking severe side effects (dose-limiting toxicities) during the first month after treatment.

Day 30 after CAR T-cell infusion

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Safety Profile of Anti-CD19/CD22 CAR T-cells
Zeitfenster: First day of CAR T-cell infusion (Day 0) through 12 months after infusion

To describe the safety profile related to the infusion of anti-CD19/CD22 CAR T-cells, evaluated and graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.

First day of CAR T-cell infusion (Day 0) through 12 months after infusion
Severity of Toxicities Related to Treatment with Anti-CD19/CD22 CAR T-cells
Zeitfenster: First day of CAR T-Cell infusion (Day 0) through 12 months after infusion

To record the severity of toxicities (side effects) related to the infusion of anti-CD19/CD22 CAR T-cells, evaluated and graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.

First day of CAR T-Cell infusion (Day 0) through 12 months after infusion
Percentage of Participants with Overall Response Rate
Zeitfenster: Assessed at Day 30, Day 60, Day 90, 6 months, and 12 months post-infusion

The percentage of participants whose cancer shrinks or completely disappears (complete response) following CAR T-cell treatment as assessed by standard disease response criteria for lymphoma (PET-CT imaging and clinical response assessments).

Assessed at Day 30, Day 60, Day 90, 6 months, and 12 months post-infusion
Percentage of Participants with Complete Response Rate
Zeitfenster: Assessed at Day 30, Day 60, Day 90, 6 months, and 12 months post-infusion

The percentage of participants who show a complete disappearance of all signs of cancer (complete response) following CAR T-cell treatment as assessed by standard disease response criteria for lymphoma (PET-CT imaging and clinical response assessments).

Assessed at Day 30, Day 60, Day 90, 6 months, and 12 months post-infusion

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Alexandra E. Rojek, MD, University of Chicago

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

13. Juli 2027

Primärer Abschluss (Geschätzt)

29. Oktober 2031

Studienabschluss (Geschätzt)

29. Oktober 2031

Studienanmeldedaten

Zuerst eingereicht

13. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

13. November 2026

Zuerst gepostet (Tatsächlich)

19. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

19. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

13. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren